Patents Assigned to Shijiazhuang Sagacity New Drug Development Co., Ltd.
  • Pyrimidine sulfamide derivative and preparation method and medical application thereof
    Patent number: 11319305
    Abstract: Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: May 3, 2022
    Assignee: Shijiazhuang Sagacity New Drug Development Co., Ltd.
    Inventors: Yunfu Luo, Maoyi Lei, Junmiao Li, Yu Xu, Ran Wei, Shuhui Chen
  • S1P1 AGONIST AND APPLICATION THEREOF
    Publication number: 20210300908
    Abstract: The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.
    Type: Application
    Filed: July 21, 2017
    Publication date: September 30, 2021
    Applicant: Shijiazhuang SagaCity New Drug Development Co., Ltd.
    Inventors: Lingyun WU, Peng ZHANG, Jian LI, Shuhui CHEN
  • 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor
    Patent number: 10954253
    Abstract: The present invention provides a 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one compound having an inhibitory effect on Wee1, and includes an application of the compound in treating various types of tumors.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 23, 2021
    Assignee: SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.
    Inventors: Wenyuan Qian, Chundao Yang, Zhengwei Li, Jie Li, Jian Li, Shuhui Chen
  • PDE4 inhibitor
    Patent number: 10662189
    Abstract: Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: May 26, 2020
    Assignee: SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.
    Inventors: Yunfu Luo, Chundao Yang, Maoyi Lei, Ling Liu, Guoping Hu, Jian Li, Shuhui Chen
  • Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases
    Patent number: 10604513
    Abstract: Disclosed is a compound for treating fibrosis-related diseases, and specifically disclosed are the compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 31, 2020
    Assignee: Shijiazhuang Sagacity New Drug Development Co., Ltd.
    Inventors: Neng-yang Shih, Bin Chen, Lei Zhang, Jian Li, Shuhui Chen